Abstract 285P
Background
Tumor growth and recurrence are controlled by inflammation, which may also be antagonistic to the therapeutic effect. Thus, we are targeting the IL-17 in BCG failure non-muscle invasive bladder cancer (NMIBC) patients to better understand how inflammatory cytokines contribute to tumor growth.
Methods
Between September 2021 and August 2023, 120 patients with bladder tumors were included (70 patients had BCG failure and 50 patients had BCG responsiveness). The patient's mean age (years) was 65.25 ± 11.74. The NMIBC was verified by histopathology with BCG response followed by Six weekly instillations (induction + maintenance) to make up the BCG treatment. The cystoscopic examination to evaluate tumor progression and recurrence for the follow-up following BCG failure at three and six months. Blood samples were obtained from each patient simultaneously to perform genotyping. Taq-Man Probe-based real-time polymerase chain reactions were used to study IL-17 G/A (rs2275913).
Results
The allele frequency of Interleukin-17 A -197 was significantly higher in BCG failure tumors compared to BCG-responsive cancers (P < 0.05). The expression of IL-17-197 AA/GG+GA genotype was shown to be significantly associated with both BCG failure and tumor development (AA/GG+GA; P=.035).
Conclusions
Identifying these genetic markers in NMIBC facilitates the monitoring of disease progression resulting from BCG treatment failure. Patients carrying the interleukin-17-197 AA (rs2275913) genotype exhibited a significantly elevated susceptibility to bladder tumor development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical Research.
Disclosure
All authors have declared no conflicts of interest.